Standardised Genetic Profiling of Subjects Belonging to the Italian Multicenter Registry of Prospective Surveillance of Subjects at Genetic Risk of Pancreatic Cancer

Status: Recruiting
Location: See location...
Intervention Type: Genetic
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only. Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test. Up to 3,000 participants will be enrolled in this study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Being enrolled on the IRFARPC registry

• Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020)

• Willingness to participate in saliva-swab-based genetic testing

Locations
Other Locations
Italy
Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata
RECRUITING
Verona
Contact Information
Primary
Erica Secchettin, PharmD
familiarita.aisp@gmail.com
0458126254
Backup
AISP Association
aisp.ricerca@gmail.com
340 2713112
Time Frame
Start Date: 2022-12-20
Estimated Completion Date: 2028-12-20
Participants
Target number of participants: 3000
Treatments
Other: Saliva testing swab
Subjects with familiarity with pancreatic cancer enrolled into the IRFARPC registry (NCT04095195) will be submitted to buccal swab for saliva-based genetic testing
Related Therapeutic Areas
Sponsors
Leads: Associazione Italiana per lo Studio del Pancreas
Collaborators: General and Pancreatic Surgery Unit, University of Verona, Genomica srl, Associazione Oltre La Ricerca, Fondazione Valsecchi

This content was sourced from clinicaltrials.gov